MCL Clinical Trials
1230 trials from ClinicalTrials.gov. Recruiting trials shown first.
A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT05495464·EARLY_PHASE1·M.D. Anderson Cancer Center·22 enrolled
AcalabrutinibRituximabBrexucabtagene AutoleucelCyclophosphamideFludarabine Phosphate
Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT05471843·PHASE1 / PHASE2·BeiGene·125 enrolled
BGB-11417
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
ACTIVE NOT RECRUITINGNCT05458297·PHASE2·Merck Sharp & Dohme LLC·223 enrolled
Zilovertamab vedotinNemtabrutinib
Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT04939272·PHASE1 / PHASE2·City of Hope Medical Center·8 enrolled
Copanlisib HydrochlorideVenetoclax
A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITINGNCT06561425·PHASE1 / PHASE2·Galapagos NV·130 enrolled
GLPG5101
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
ACTIVE NOT RECRUITINGNCT04911478·Adicet Therapeutics·50 enrolled
ADI-001
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT04802590·PHASE2·The Lymphoma Academic Research Organisation·194 enrolled
Ibrutinib 560 mgVenetoclax 10 MG Oral Tablet [Venclexta]Venetoclax 50 MG Oral Tablet [Venclexta]Venetoclax 100 MG Oral Tablet [Venclexta]
Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT05214183·PHASE2·Nordic Lymphoma Group·81 enrolled
Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITINGNCT05025800·PHASE1 / PHASE2·M.D. Anderson Cancer Center·47 enrolled
CD47 Antagonist ALX148LenalidomideRituximab
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
ACTIVE NOT RECRUITINGNCT05024045·PHASE1·Eli Lilly and Company·316 enrolled
LOXO-338Pirtobrutinib
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
ACTIVE NOT RECRUITINGNCT05020678·PHASE1·Nkarta, Inc.·150 enrolled
NKX019
Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT04765111·PHASE2·M.D. Anderson Cancer Center·53 enrolled
AcalabrutinibRituximab
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
ACTIVE NOT RECRUITINGNCT04662255·PHASE3·Loxo Oncology, Inc.·500 enrolled
PirtobrutinibIbrutinibAcalabrutinibZanubrutinib
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT04783415·PHASE2·City of Hope Medical Center·12 enrolled
AcalabrutinibUblituximabUmbralisib
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT04718883·PHASE2·Shanghai Ming Ju Biotechnology Co., Ltd.·59 enrolled
CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL
ACTIVE NOT RECRUITINGNCT04624958·PHASE2·Sun Yat-sen University·42 enrolled
Zanubrutinib and RituximabR-DHAOxZanubrutinib Maintenance
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
ACTIVE NOT RECRUITINGNCT04072458·PHASE1·Bio-Path Holdings, Inc.·30 enrolled
L-Bcl-2 antisense oligonucleotide
Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT04189757·PHASE2·M.D. Anderson Cancer Center·9 enrolled
Acalabrutinib
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT03282396·PHASE2·M.D. Anderson Cancer Center·20 enrolled
Ibrutinib
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
ACTIVE NOT RECRUITINGNCT04205409·PHASE2·University of Washington·20 enrolled
Nivolumab
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
ACTIVE NOT RECRUITINGNCT03932331·PHASE1 / PHASE2·AstraZeneca·105 enrolled
Acalabrutinib
Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT04234061·PHASE2·Peter MacCallum Cancer Centre, Australia·20 enrolled
ibrutinib and Tisagenlecleucel
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
ACTIVE NOT RECRUITINGNCT03842696·PHASE1 / PHASE2·University of Michigan Rogel Cancer Center·43 enrolled
VorinostatBlood and Marrow Transplant (BMT)Tacrolimus (or cyclosporine)MethotrexateMycophenolate Mofetil (MMF)+1 more
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT04115631·PHASE2·ECOG-ACRIN Cancer Research Group·360 enrolled
AcalabrutinibBendamustineBendamustine HydrochlorideCytarabineRituximab
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
ACTIVE NOT RECRUITINGNCT03888105·PHASE2·Regeneron Pharmaceuticals·515 enrolled
Odronextamab
ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)
ACTIVE NOT RECRUITINGNCT04049513·PHASE1·Malaghan Institute of Medical Research·30 enrolled
WZTL002-1 (1928T2z CAR-T cells)Cyclophosphamide and Fludarabine lymphodepleting chemotherapy
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
ACTIVE NOT RECRUITINGNCT03863184·PHASE2·Weill Medical College of Cornell University·37 enrolled
AcalabrutinibLenalidomideRituximabObinutuzumab
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
ACTIVE NOT RECRUITINGNCT04007029·PHASE1·Jonsson Comprehensive Cancer Center·24 enrolled
Chimeric Antigen Receptor T-Cell TherapyCyclophosphamideFludarabine PhosphateTocilizumab
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
ACTIVE NOT RECRUITINGNCT04002297·PHASE3·BeiGene·510 enrolled
zanubrutinibbendamustinerituximab
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT03946878·PHASE2·M.D. Anderson Cancer Center·32 enrolled
AcalabrutinibVenetoclax